Skip to main content

Advertisement

Table 3 Principle outcomes of the constant effect analyses*

From: Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis

  Comparator
Treatment No drug treatment Rivastigmine Donepezil Galantamine
   1–4 mg 6–12 mg 5 mg 10 mg 16 mg
Rivastigmine       
1–4 mg 3.0%** $2,880 $224,222      
6–12 mg 5.8% $514 $36,161 3.0% -$2,370 Dominant     
Donepezil       
5 mg 6.6% $1,032 $36,161 3.7% -$1,849 Dominant 0.8% $522 $158,875    
10 mg 9.5% -$811 Dominant 6.7% -$3,692 Dominant 3.9% -$1,321 Dominant 3.1% -$1,843 Dominant   
Galantamine       
16 mg 10.2% -$1,134 Dominant 7.5% -$4,015 Dominant 4.6% -$1,644 Dominant 3.9% -$2,166 Dominant 0.8% -$323 Dominant  
24 mg 10.3% -$1,366 Dominant 7.6% -$4,246 Dominant 4.7% -$1,876 Dominant 4.0% -$2,398 Dominant 0.9% -$555 Dominant 0.1% -$232 Dominant
  1. * for each drug treatment in the rows the comparison is made relative to the approach in the column ** percent reduction in time spent requiring FTC net costs incremental cost per QALY gained